Opioid Use for Chronic Pain
Student’s Name
Institutional Affiliation
Professors Name
Course Title
Due Date
Introduction
The use of Opioids is often seen as controversial within the chiropractic industry. Opioids, commonly known as a pain-relieving drug, have been used throughout all human history. But how necessary are they for chronic pain? Chronic pain, often a pain associated with chiropractic patients, can cause persistent discomfort that patients endure for prolonged durations. Chronic pain is unrelated to the patient’s initial diagnosis or injury; instead, it relates to the nervous system’s changes that keep the nerves in a constant pain signaling state. While Opioids may be a ‘quick fix’ to relieve pain, the drug’s durability is often problematic. It can result in long term destruction, which also contradicts the philosophy of Chiropractic. The most common cause of destruction inflicted by opioids is addiction. This paper, therefore, explains why Opioids should not be used for the treatment of chronic pain.
Body
First, the use of opioids may result in addiction. Drug addiction is a rising problem mainly caused by patients abusing the prescribed medication. A fraction of prescribed patients find themselves increasing dose without prescription; others go to different doctors to obtain more opioids, some purposefully sedate, reserve pain medication, and use them for other purposes than relieving pain. Healthcare professionals should be vigilant of medical dosage increments, prescriptions misplace, and early refill requests by patients since such behaviors are suggestive of abuse. It is also vivid in some studies that opioid misuse is common among general practice patients. Long-term opioid treatment is linked with an 87% mortality rate increase (Campbell et al., 2016). Opioid abusers are more likely to be depressed, have anxiety disorders, and bipolar compared to non-abusers. Most opioid abusers are the potential to resort to inpatient mental health services. Also, there are a variety of alternative treatments for chronic pain. Considering the adverse effects that might be followed by the use of opioids, it is wise to use alternative treatment options with little or no side effects. In the general class of medications, topical and oral therapies can be used for treating chronic pain. Oral medications are taken by mouth, and they include acetaminophen and anti-inflammatory drugs. Medications that are applied to the skin are also available. They can be a cream or an ointment or a patch applied to the skin. Patches are used on the skin right on top of the painful zone, where the dynamic drug is unconstrained. An example of the active drug is lidocaine.
Additionally, Opioids are not effective over a prolonged course. Though analgesic efficacy is initially excellent, it is not often continued during long term opioid therapy. Despite stable pain and escalation of dose, maintenance of the opioids’ analgesic efficacy over prolonged courses of treatment is still a significant problem (Nielsen et al., 2017). Bearing in mind the possibly severe adverse effects of opioids, the impression that pain relief could shrink over time may have a considerable influence on the choice to embark on this therapy, particularly in susceptible persons. The potential loss of analgesic efficacy is chiefly concerning, bearing in mind that dependence may make it difficult to get rid of opioid therapy even when poor analgesia is inevitable. There are several ways in which analgesic efficacy is lost over time; such methods include intermittent withdrawal, subtle withdrawal, opioid-induced hyperalgesia, pharmacologic tolerance, and psychological factors like placebo component loss. There are other patches like fentanyl that are placed far from the painful zone. There are also other methods of pain relief that do not include medications. These activities help relieve pain and reduce the medications required for pain relief (Holliday et al., 2017). Examples of such activities are exercises under a physical therapist and substitute modalities like acupuncture. Apart from oral and topical medications, there are interventional approaches that encompass injection about numerous spinal area points. These techniques involve moderately shallow injections into the pain muscles- trigger point injections and more aggressive processes. Various procedures range from epidural injections, facet injections to injections for burning pain of arms and legs due to Reflex Sympathetic Dystrophy or Complex Regional pain syndrome (CRPS).
Moreover, Opioid neurotoxicity is a significant issue, particularly among the elderly. Sedation and dizziness are also central nervous system effects resulting from unpremeditated costs among those getting long-term opioid medication, like respiratory depression, fissures, and falls. Hyperalgesia related to extreme sensitivity to pain has been reported in chronic opioid medication patients. Additionally, patients on regular opioid medication have been revealed to have reasonably greater heights of comorbid clinical depression of up to around 39%. Fascinatingly, it has been shown that patients on chronic opioid medication with comorbid mental illness have a considerably advanced sum of emergency room appointments. A related use of other central nervous system sedatives such as alcohol, benzodiazepines, and barbiturates intensifies respiratory depression, resulting in apnea. Furthermore, opioids are associated with constipation. A study by Omeed et al., 2020 on Opioid-Induced Constipation states that around 50% of patients receiving opioid chronic treatments are victims of Opioid-Induced Constipation. OIC may strike immediately once the patient takes the opioid or may show gradually during opioid medication. Opioid drugs hinder peristalsis and gastric emptying in the GI tract leading to delayed medical absorption and increased fluid absorption. Constipation and stool hardening result from a lack of fluid in the intestine. Most patients reported having OIC complain of incomplete emptying of the rectum during defecation. Opioids increase the anal sphincter tone tampering with the defecation reflex; some patients experience an anal blockage. Moreover, opioids decrease bile and pancreatic juice emptying resulting in delayed digestion. Side effects like straining, nausea, abdominal pain, bloat, and vomiting are linked with constipation. Most patients who suffer from opioid medication’s constipation opt-out to tolerate constipation’s severe effects on their GI tract. Once the development of constipation to opioids has started, the relief with medication is sluggish and doesn’t often lead to ideal comfort from Opioid-Induced Constipation. Due to this constipation, additional therapies (pharmacological and non-pharmacological) are included in the process. Unemployed, older, and female patients are more likely to show OIC.
Also, Overall sleep quality can be severely impacted by the use of opioids. According to research conducted by the University of Penn State, patients who reported low sleep quality were associated with intense opioid cravings (Nicholas, 2019). The sleep issues included frequent wake up throughout the night and restless sleep. In instances that opioids interfere with sleep, they cause four separate kinds of problems. An individual may have on sleep issues while others may be having more than one type of challenge, including parasomnia, insomnia, mixed and daytime sleepiness. For parasomnia, opioids interfere with patients’ sleep cycles and patterns; they result in abnormal sleep behaviors, making them restless sleep. Moreover, opioids might result in insomnia, whereby patients have sleep deprivation challenges, the difficulty of staying asleep, or not getting enough sleep. Patients might not feel rest from normal sleep. Also, opioids may make an individual have excessive sleep during daytime hours. In some instances, the tiredness results from sleep issues, and in some of the cases, there is no clear explanation. Further, opioid use results in a combination of all the challenges with no main type. For instance, a patient might have behaviors during sleep, along with daytime sleep. Nevertheless, the use of opioids has been identified to block and disrupt access to rapid eye movement, which is one of the essential sleep stages. According to Medical News Today, rapid eye movement accounts for approximately 25% of adults’ sleep each night (Nicholas, 2019). The deep stage of rapid eye movement is more critical in repairing bone and muscle tissue and strengthening the immune system. Patients struggling with extensive use of opioids experience nightmares and vivid dreams during rapid eye movement stages.
Furthermore, opioid has been thought to be the most efficient and effective pain reliever as it has been used for several years. Every individual believes that opioids are the most efficient pain relievers. In contrast, recent studies have identified that ibuprofen and acetaminophen together are the most powerful medications in treating acute pain (Islam, 2019). As a result, patients and medical professionals need to understand opioid medication history and the potential significance of using (NSAIDs) nonsteroidal anti-inflammatory drugs instead. For millennia, opioid has been among the most efficient and effective medications in the treatment of pain. Its use in managing chronic or acute pain related to advanced medical complications is regarded as the global care standard. However, the long term use of opioids in treating severe non-cancer pains continues to bring controversies. Concerns related to safety, effectiveness, abuse, and misuse have over the years, and in some instances, driving an enhanced restrictive perspective and greater willingness to administer the drug. In the United States, over the past decades has been characterized by approaches that have repeatedly shifted in response to epidemiological and clinical events and observations in the regulatory and legal communities. The interface between the legitimacy in the medicinal use of opioids in providing analgesia and the phenomenon related to addiction and abuse continues to challenge the clinical world (Islam, 2019). Historically, addiction concerns have contributed to the under-treatment of conditions widely considered suitable for opioid therapy, such as the end of life pain, acute pain, and cancer pain. Undertreatment of severe pain among individuals addicted might result in adverse, personal, social, and medical consequences associated with continued drug-seeking behavior. Besides, complaints on pain may be more problematic among individuals addicted to opioids as they inhibit lower tolerance for pain than other addicted persons.
Lastly, opioid prescription has been associated with harm according to a Relieving Pain report in America by the Institute of Medicine (IOM) (Kovitwanichkanont & Day, 2018). The more number of days for which prescription is administered to individuals and the higher the dosage, the more exposure risk. Prescription of opioids for chronic pain by CDC guidelines urges prescribers to give the lowest effective dosages and prescribe a dose with no greater quantity than the need for expected pain duration severe enough to need opioids. Besides, other dispensing and prescribing patterns suggest some additional challenges for overdose and OUD. Risk exposure timing, for example, contributes to iatrogenic overdoses. Also, the acquisition of opioids from multiple pharmacies and prescribers and prescriptions that overlap has been associated with high overdose risks. The patterns reflect poor coordination of care for OUD in the community and individuals with pain rather than the casual epidemiology of nonmedical drivers used in prescription opioids. Moreover, a more significant number of analgesic prescribing behaviors on opioids significantly contribute to prolonged exposure of opioids and patient risks, including MME calculation errors, inconsistency in the monitoring of opioid administration, drug monitoring programs underutilization, etc. One significant aspect of opioid prescription monitored by the FDA is drug-drug interventions, where the simultaneous use of some medications may change patients’ risk (Kovitwanichkanont & Day, 2018). Some medicines are more frequently prescribed based on pain co-occurrence with other conditions and are usually widely monitored. Individuals might result in co-using other medications with opioids to achieve prolonged or heightened euphoric or analgesic effects. However, trends in illicit drug markets and heroin use significantly impact public health on prescription opioid use. One cannot measure the significance of new treatments without taking the main account of unintended harm from transition and diversion to illicit use of opioids.
Conclusion
In conclusion, while opioids may be necessary for acute or more severe pain, they can be overused and lethal when not used correctly. Patient types or levels of risk from a particular opioid are influenced by specific medication features, including Route of administration, formulation, and the compound. Also, Opioid prescriptions may, in some instances, influence overdose risks in patients. Therefore, medical communities need to address this unsafe pain treatment and change the standards of practice in guiding the care that is more important for what the patients deserve and need.
References
Campbell, G., Bruno, R., Darke, S., Shand, F., Hall, W., Farrell, M., & Degenhardt, L. (2016). Prevalence and correlates of suicidal thoughts and suicide attempts in people prescribed pharmaceutical opioids for chronic pain. The Clinical journal of pain, 32(4), 292-301. Retrieved from https://www.ingentaconnect.com/content/wk/cjpn/2016/00000032/00000004/art00003
Holliday, S. M., Hayes, C., Dunlop, A. J., Morgan, S., Tapley, A., Henderson, K. M., … & Spike, N. A. (2017). Does brief chronic pain management education change opioid prescribing rates? A pragmatic trial in Australian early-career general practitioners. Pain, 158(2), 278-288. Retrieved from https://journals.lww.com/pain/Abstract/2017/02000/Does_brief_chronic_pain_management_education.12.aspx
Islam, M. M. (2019). Pattern and probability of dispensing prescription opioids and benzodiazepines among the new users in Australia: a retrospective cohort study. BMJ Open, 9(12). Retrieved from http://dx.doi.org/10.1136/bmjopen-2019-030803
Kovitwanichkanont, T., & Day, C. A. (2018). Prescription opioid misuse and public health approach in Australia. Substance use & misuse, 53(2), 200-205. Retrieved from https://doi.org/10.1080/10826084.2017.1305415
Nicholas, R. (2019). Pharmaceutical opioids in Australia: A double-edged sword. National Centre for Education and Training on Addiction (NCETA), Flinders University, Adelaide. Retrieved from http://nceta.flinders.edu.au/files/2415/4960/5275/Pharmaceutical_opioids_in_Australia_A_double-edged_sword.pdf
Nielsen, S., Gisev, N., Bruno, R., Hall, W., Cohen, M., Larance, B., … & Pearson, S. (2017). Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiology and drug safety, 26(5), 587-591. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4168